Episode 1562 • • 1:13:50 - 1:18:30
1562: Tink Tank
Moderna and Merck, Melanoma Vaccine, mRNA Technology
Moderna and Merck released trial results for a personalized mRNA cancer vaccine used in conjunction with the immunotherapy drug Keytruda. The combination therapy reportedly showed a 65% reduction in the recurrence of stage 3 and 4 melanoma. Unlike traditional vaccines, this treatment is customized to the genetic sequence of an individual patient's tumor.